PTGX is a clinical stage biotech with a pipeline of Colitis & Crohns treatments
PTGX recently discontinued its lead asset's Ph2b trial, later blaming it on their CRO's human error.
TBPH competing molecule is now in the lead in the intestinally restricted Ulcerative Colitis (UC) race to approval.
The problem with the PTGX GI platform is slow onset. Its strength is minimal immunosuppression. A problem with TBPH's UC treatment is systemic immunosuppression ( but with relatively quicker onset ).
Market Data 
Markets 
AI
